Development of AD214 a novel anti-fibrotic treatment for advanced Age related macular degeneration [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description Age related macular degeneration remains the leading cause of blindness in this and other industrialised countries. Although treatment is available for an advanced form of the disease, many do not respond, or lose significant amounts of vision with long term treatment. This proposal will provide critical data for commericalizing a novel therapy called an i-body (AD214), that reduces vision loss in this disease by blocking the formation of scarring with reduced need for injections.

Funding Amount $687,994

Funding Scheme Development Grants

Chief Investigator Prof Erica Fletcher

Notes Development Grant